Secondary stroke prevention with antiplatelet drugs: Have we reached the ceiling?

International Journal of Stroke

Volumn 1, Issue 1, 2006, Pages 4-8

  Diener, Hans Christoph ^a  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; DIPYRIDAMOLE; FIBRINOGEN RECEPTOR ANTAGONIST; LOTRAFIBAN; TICLOPIDINE;

BLEEDING; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DEATH; DRUG EFFICACY; DRUG FATALITY; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENCY; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; LOW DRUG DOSE; PATIENT SELECTION; PRIORITY JOURNAL; RECURRENCE RISK; REVIEW; RISK REDUCTION; SECONDARY PREVENTION; STROKE; TRANSIENT ISCHEMIC ATTACK;

AGE FACTORS; AGED; ASPIRIN; CLINICAL TRIALS AS TOPIC; DIPYRIDAMOLE; DRUG THERAPY, COMBINATION; HUMANS; ISCHEMIC ATTACK, TRANSIENT; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; RECURRENCE; RISK ASSESSMENT; STROKE; TICLOPIDINE; TIME FACTORS;

EID: 33646689990     PISSN: 17474930     EISSN: 17474949     Source Type: Journal    
DOI: 10.1111/j.1747-4949.2005.00016.x     Document Type: Review

References (36)

1. Wilterdink JL, Easton JD: Vascular event rates in patients with atherosclerotic cerebrovascular disease. Arch Neurol 1992; 49: 857-63.
2. Weimar C, Kraywinkel K, Rodl J et al. Etiology, duration, and prognosis of transient ischemic attacks: An analysis from the German Stroke Data Bank. Arch Neurol 2002; 59: 1584-8.
3. Grau AJ, Weimar C, Buggle F et al. Risk factors, outcome, and treatment in subtypes of ischemic stroke: The German stroke data bank. Stroke 2001; 32: 2559-66.
4. Lovett J, Coull A, Rothwell P: Early risk of recurrence by subtype of ischemic stroke in population-based incidence studies. Neurology 2004; 62: 569-73.
5. Rothwell PM, Warlow CP: TimTng of TIAs preceding stroke: time window for prevention is very short. Neurology 2005; 64: 817-20.
6. Johnston SC, Gress DR, Browner WS et al. Short-term prognosis after emergency department diagnosis of TIA. JAMA 2000; 284: 2901-6.
7. Antithrombotic Trialists' Collaboration: Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 524: 71-86.
8. Antiplatelet Trialists Collaboration: Collaborative overview of randomised trials of antiplatelet therapy -I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994; 308: 81-106.
9. Antiplatelet Trialists Collaboration: Secondary prevention of vascular disease by prolonged antiplatelet treatment. BMJ 1988; 296: 320-31.
10. Patrono C, Roth GJ: Aspirin in ischemic cerebrovascular disease. Stroke 1996; 27: 756-60.
11. Tran H, Anand SS: Oral antiplatelet therapy in cerebrovascular disease, coronary artery disease, and peripheral arterial disease. JAMA 2004; 292: 1867-74.
12. Algra A, van Gijn J: Cumulative meta-analysis of aspirin efficacy after cerebral ischaemia of arterial origin. J Neurol Neurosurg Psychiatry 1999; 65: 255.
13. The Dutch TIA Trial Study Group: A comparison of two doses of aspirin (30 mg vs. 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke. N Engl J Med 1991; 325: 1261-6.
14. UK-TIA Study Group: The United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: Final results. J Neurol Neurosurg Psychiatry 1991; 54: 1044-54.
15. Diener HC, Cuhna L, Forbes C et al. European Stroke Prevention Study 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 1996; 143: 1-13.
16. Topol E, Easton D, Harrington R et al. Randomized, double-blind, placebo-controlled, international trial of the oral IIb/IIIa antagonist lotrafiban in coronary and cerebrovascular disease. Circulation 2003; 108: 16 -23.
17. Hass WK, Easton JD, Adams HP et al. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke. N Engl J Med 1989; 321: 501-7.
18. Gent M, Blakely JA, Easton JD et al. The Canadian American ticlopidine study (CATS) in thromboembolic stroke. Lancet 1989; i: 1215-20.
19. CAPRIE Steering Committee: A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348: 1329-39.
20. Ringleb P, Bhatt D, Hirsch A et al. Benefit of clopidogrel over aspirin is amplified in patients with a history of ischemic events. Stroke 2004; 35: 528-32.
21. Bhatt DL, Marso SP, Hirsch AT et al. Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus. Am J Cardiol 2002; 90: 625-8.
22. Bhatt D, Chew D, Hirsch A et al. Superiority of clopidogrel versus aspirin in patients with prior cardiac surgery. Circulation 2001; 103: 363-8.
23. Bhatt D, Foody J, Hirsch A et al. Complementary, additive benefit of clopidogrel and lipid-lowering therapy in patients with atherothrombosis. J Am Coll Cardiol 2000; 35 (Suppl A): 326.
24. Diener H, Bogousslavsky J, Brass LM et al. Management of atherothrombosis with clopidogrel in high-risk patients with recent transient ischaemic attack or ischaemic stroke (MATCH): Study design and baseline data. Cerebrovasc Dis 2004; 17: 253-61.
25. Diener H, Bogousslavsky J, Brass L et al. Acetylsalicylic acid on a background of clopidogrel in high-risk patients randomised after recent ischaemic stroke or transient ischaemic attack: The MATCH trial results. Lancet 2004; 364: 331-4.
26. Yusuf S, Zhao F, Mehta SR et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345: 494-502.
27. Markus HS, Droste DW, Kaps M et al. Dual antiplatelet therapy with clopidogrel and aspirin in symptomatic carotid stenosis evaluated using doppler embolic signal detection: The Clopidogrel and Aspirin for Reduction of Emboli in Symptomatic Carotid Stenosis (CARESS) trial. Circulation 2005; 111: 2233-40.
28. Diener HC, Forbes C, Riekkinen PJ et al. European stroke prevention study 2: Efficacy and safety data. J Neurol Sci 1997; 151 (Suppl): S1-77.
29. The ESPS Group: The European Stroke Prevention Study (ESPS). Principal end- points. Lancet 1987; ii: 1351-4.
30. Bousser MG, Eschwege E, Haguenau M et al. 'A.I.C.L.A.' Controlled trial of aspirin and dipyridamole in the secondary prevention of atherothrombotic cerebral ischemia. Stroke 1983; 13: 5-14.
31. Acheson J, Danta G, Hutchinson EC: Controlled trial of dipyridamole in cerebral vascular disease. BMJ 1969; 1: 614-5.
32. American-Canadian Co-operative Study Group: Persantin-aspirin in cerebral ischemia, part II: Endpoint results. Stroke 1985; 16: 406-15.
33. Leonardi-Bee J, Bath PM, Bousser MG et al. Dipyridamole for preventing recurrent ischemic stroke and other vascular events: A meta-analysis of individual patient data from randomized controlled trials. Stroke 2005; 36: 162-8.
34. Sacco RL, Sivenius J, Diener HC: Efficacy of aspirin plus extended-release dipyridamole in preventing recurrent stroke in high-risk populations. Arch Neurol 2005; 62: 403-8.
35. Diener HC Modified-release dipyridamole combined with aspirin for secondary stroke prevention. Aging Health 2005; 1: 19-26.
36. Diener HC, Ringleb PA, Savi P: Clopidogrel for secondary prevention of stroke. Expert Opin Pharmacother 2005; 6: 755-64.